LSV Asset Management
HZNP

LSV Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

LSV Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-25,800
Closed -$306K – 1019
2017
Q2 		$306K Hold
25,800
– – ﹤0.01% 909
2017
Q1 		$381K Hold
25,800
– – ﹤0.01% 886
2016
Q4 		$417K Buy
+25,800
New +$468K ﹤0.01% 877

Other funds holding HZNP

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

LSV Asset Management's HZNP Position: Q3 2017 in Review

LSV Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2017, closing a stake of 25,800 shares — an estimated $306K sold.

LSV Asset Management first reported a position in HZNP in Q4 2016 and held it in 3 quarters. The position peaked at $417K in Q4 2016. 181 funds tracked by Wall St. Rank hold HZNP as of Q3 2017.

  • LSV Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • LSV Asset Management sold 25,800 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2017, an estimated $306K.
  • LSV Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 3 quarters.
  • LSV Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $417K in Q4 2016.
  • 181 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2017.

Based on LSV Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.